Core Insights - AdvaMed has proposed nearly a dozen recommendations to enhance U.S. medtech production and exports in response to the Commerce Department's Section 232 investigation initiated by the Trump administration [1][3] Recommendations - Establish a preferred trading bloc with NATO partners and allies to foster growth in U.S. medtech R&D and manufacturing [2][4] - Continue the USMCA qualifying products rule for Mexico and Canada to ensure resilient and affordable medical technology supply chains in North America [4] - Expand the qualifying rule to include Costa Rica and the Dominican Republic to diversify supply chains and reduce dependence on adversarial suppliers [4] - Pursue bilateral medtech commitments from key global markets, specifically urging fair treatment of American products in regulatory and procurement processes from China and India [4]